The FDA vote putting patients in danger

0
156

That is why the latest vote by the FDA’s Pharmacy Compounding Advisory Committee deserves far more scrutiny than it has received.

According to STAT, the advisory panel narrowly recommended that compounding pharmacies be allowed to manufacture several unapproved peptides, including BPC-157, KPV, TB-500, and MOTS-c. The vote was framed as a win for Health and Human Services Secretary Robert F. Kennedy Jr. and for peptide proponents. But the most troubling detail was in the subheadline: a majority of the panelists who voted yes reportedly had ties to the peptide industry.

IT’S NOT THE NICOTINE, IT’S THE SMOKE. DOCTORS ARE STILL GETTING THIS WRONG

That is not a footnote. It is the heart of the problem.

As physicians, we prescribe off-label all the time. A drug may be approved for one condition but used for another when evidence, experience and patient need support it. Off-label…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here